Alice Melao,  —

Articles by Alice Melao

Givosiran Treatment Leads to 74% Drop in Acute Hepatic Porphyria Attacks, Phase 3 Data Show

Treatment with investigational RNA-based therapy givosiran can safely reduce the annual incidence of acute hepatic porphyria (AHP) attacks, according to final results from a Phase 3 clinical trial. These positive results from the ENVISION trial are intended to support the application for regulatory approval that givosiran’s manufacturer Alnylam Pharmaceuticals is planning…